Snapshot from Sep 20, 2026 at 07:00 UTC. For live data and tracking: View Live
Business licensing agreement

Thryv licenses SGK1 inhibitors from CSIC/UAM

Analysis based on 6 articles · First reported Sep 03, 2026 · Last updated Sep 03, 2026

Sentiment
30
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The licensing agreement expands Thryv's pipeline into neurodegenerative diseases, potentially increasing its valuation and attractiveness to investors. It also strengthens Thryv's intellectual property portfolio with a second independent SGK1 inhibitor scaffold, which may enhance its competitive position in the biopharmaceutical market.

Biopharmaceuticals Biotechnology

Ajax Therapeutics Inc., a clinical-stage biopharmaceutical company developing selective SGK1 inhibitors, announced on September 3, 2026 that it entered into an exclusive, worldwide, royalty-bearing patent and know-how license agreement with the Spain — Spanish National Research Council (CSIC), the Autonomous University of Madrid (UAM), and Fundación de la Universidad Autónoma de Madrid (FUAM). The agreement, effective July 1, 2026, grants Thryv rights across all fields of use and territories, with the right to sublicense. The licensed invention is a structurally distinct SGK1 inhibitor scaffold developed by research groups led by Ana Martínez, Carmen Gil, Eduardo Oliver Pérez at CSIC, and Isabel Lastres-Becker and Ana Briones Alonso at UAM. This second independent chemical series is intended to enable Thryv to develop compounds designed to reach the brain, targeting neurodegenerative diseases such as Parkinson's and Alzheimer's, while its existing cardiac programs continue. Thryv's lead asset, THRV-1268, is in clinical studies for Long QT Syndrome Type 2 and heart failure. The newly licensed series will undergo initial characterization immediately, with a first development candidate targeted for 2027.

priv
Ajax Therapeutics is the licensee and primary beneficiary, gaining exclusive worldwide rights to a new SGK1 inhibitor scaffold, expanding its pipeline into neurodegenerative diseases and potentially increasing its market value.
Importance 100.0 Sentiment 70.0
govactor
CSIC is a licensor, receiving royalties and recognition for its research, but the financial impact is modest compared to Thryv's potential gains.
Importance 80.0 Sentiment 40.0
oth
UAM is a licensor, benefiting from royalty income and enhanced reputation in neurodegenerative research, though the direct financial impact is limited.
Importance 80.0 Sentiment 40.0
ngo
FUAM is a licensor, receiving royalties as part of the agreement, with a minor role in the event.
Importance 60.0 Sentiment 30.0
per
Ana Martínez is a lead researcher whose work contributed to the licensed invention, gaining recognition but no direct financial benefit.
Importance 50.0 Sentiment 30.0
per
Carmen Gil is a lead researcher whose work contributed to the licensed invention, gaining recognition but no direct financial benefit.
Importance 50.0 Sentiment 30.0
per
Eduardo Oliver Pérez is a lead researcher whose work contributed to the licensed invention, gaining recognition but no direct financial benefit.
Importance 50.0 Sentiment 30.0
per
Isabel Lastres-Becker is a lead researcher whose work contributed to the licensed invention, gaining recognition but no direct financial benefit.
Importance 50.0 Sentiment 30.0
per
Ana Briones Alonso is a lead researcher whose work contributed to the licensed invention, gaining recognition but no direct financial benefit.
Importance 50.0 Sentiment 30.0
per
Debra Odink, as President and Chief Development Officer, is a key spokesperson and leader in the deal, but her personal financial impact is indirect.
Importance 40.0 Sentiment 30.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.